ArticleProceedings of the National Academy of Sciences of the United States of America2017

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Udupi A Ramagopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.